secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001193125-24-246171
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics: Phase 2 LD IL-2 in Alzheimer's meets endpoints, shows cognitive stabilization
--------------------------------------------------------------------------------

- Study met primary safety endpoint and secondary endpoint for Treg expansion with no off-target effects.
- LD IL-2 q4wks showed cognitive stabilization (ADAS-Cog14 4.93-point improvement vs placebo, p=0.061).
- Significant improvement in CSF Aß42 (p=0.045) and trend toward stabilizing CSF NfL (p=0.060) with q4wks.
- Company likely advancing LD IL-2 q4wks; supports COYA 302 combination in ALS and FTD.
- No serious adverse events or deaths; common AEs were mild injection-site erythema and eosinophil increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524246171/0001193125-24-246171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312524246171/d821192d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-246171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer